Status:
UNKNOWN
Effect of Angiotensin-Neprilysin Inhibition (ARNI) on Prognosis of Chronic Heart Failure
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University
Collaborating Sponsors:
Baoji Central Hospital
Conditions:
Chronic Heart Failure
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study is a randomized controlled multicenter clinical trial, in which about 340 patients with newly diagnosed or prior diagnosed chronic heart will be recruited. Patients will be randomly divided...
Detailed Description
Chronic heart failure is associated with poor prognosis in cardiac patients, although systemic effective drugs has been applied in these patients. European Society of Cardiology (ESC) has recommended ...
Eligibility Criteria
Inclusion
- Age ≥ 18
- HFrEF, defined as LVEF≤40% and New York Heart Association (NYHA) class ≥ II.
- Plasma NT-proBNP ≥ 600 pg/ml, or NT-proBNP ≥ 400 pg/ml if patients have been hospitalized for heart failure in 12 months.
- If patients have been taking ACEI/ARB at recruitment, a stable dose equivalent to at least 10mg/day of enalapril will be required.
- Volunteer for the study and sign the informed consent.
Exclusion
- Symptomatic hypotension, systolic blood pressure \< 95 mmHg at baseline.
- eGFR \< 30 ml(/min\*1.73m2) at baseline.
- Serum potassium \> 5.4 mmol/L at baseline.
- Contraindication of ACEI or ARB.
Key Trial Info
Start Date :
June 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 31 2022
Estimated Enrollment :
340 Patients enrolled
Trial Details
Trial ID
NCT03821701
Start Date
June 1 2018
End Date
January 31 2022
Last Update
August 7 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China, 710000